阿奇霉素联合孟鲁司特治疗咳嗽变异性哮喘的临床观察

Therapeutic Effect of Azithromycin and Montelukast on Mycoplasma pneumoniae Induced Cough Variant Asthma

目的观察阿奇霉素联合孟鲁司特钠对肺炎支原体感染后诱发的咳嗽变异性哮喘的疗效及预后影响。方法将132例肺炎支原体感染后诱发的咳嗽变异性哮喘患儿随机分为两组,治疗组67例予以阿奇霉素、孟鲁司特钠口服治疗;对照组65例单用阿奇霉素口服治疗。两组患儿均口服丙卡特罗及酮替芬进行基础治疗,严重发作时加用泼尼松龙短程口服。比较两组咳嗽缓解率、复发率。结果联用组患儿咳嗽缓解率为97.0%,咳嗽复发率为26.9%;单用阿奇霉素组患儿咳嗽缓解率为40.0%,咳嗽复发率为70.8%,两组比较差异有统计学意义(P<0.01)。结论阿奇霉素联合孟鲁司特能明显提高肺炎支原体感染后诱发咳嗽变异性哮喘的疗效,降低咳嗽复发率,有利于预后。

Objective To study the curative effect of Azithromycin combined with Montelukast sodium and prognosis of Mycoplasma pneumoniae （MP） induced cough variant asthma （CVA）. Methods 132 CVA cases evoked by MP were divided randomly into two groups：the therapeutic group （67 cases）,were given Azithromycin and Montelukast sodium orally, and the control group （65 cases）, were treated only by Azithromycin orally. The two groups of children were received the basic treatment with procaterol and ketotifen orally, plus short-range oral Administration of prednisolone while severe attack. The remission rate and recurrence rate of cough between the two groups were compared. Results The remission rate and recurrence rate of cough of the therapeutic group were 97.0% and 26.9%, respectively while those of the control group were 40.0% and 70.8%, respectively. The difference between two groups was statistically significance （all P〈 0.01 ）. Conclusion Azithromycin combined with Montelukast can significantly improve the curative effect of CVA evoked by MP, reduce the recurrence rate and conducive to the prognosis.